Search clinical trials for: Recombinant vaccine

Total 12574 results

Universidad de Valparaiso
GlaxoSmithKline; Roche Pharma AG; Aclin Laboratory

Completed

Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV . (CORE-HIV)

Hepatitis B | HIV

Chile
National Institute of Allergy and Infectious Diseases...

Completed

Safety of Sublingual dmLT for ETEC

Gastroenteritis Escherichia Coli

United States
Jun Zhang
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Completed

Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls

Cervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent Infection

China
DynPort Vaccine Company LLC, A GDIT Company

Withdrawn

Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B (rBV A/B)

Botulism
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID); Beth Israel... and other collaborators

Completed

A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults (MENSCH)

Healthy

United States
Merck Sharp & Dohme LLC

Completed

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Papillomavirus Infections
GlaxoSmithKline

Completed

Combined Study - Phase 3b MenB Long Term Persistence in Adolescents

Infections, Meningococcal

Chile, Canada, Australia
Novartis Vaccines

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

Meningococcal Disease

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

Influenza A Virus, H7N9 Subtype

United States
Abramson Cancer Center of the University of Pennsylvania

Withdrawn

A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian, Fallopian Tube and Peritoneal Cancer

United States
Shanghai Bovax Biotechnology Co., Ltd.

Completed

A Phase I Study of Quadrivalent HPV Recombinant Vaccine

HPV Infections

China
Serum Institute of India Pvt. Ltd.
PATH

Completed

Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization

Rotavirus Gastroenteritis

India
National Institute of Allergy and Infectious Diseases...

Completed

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
Merck Sharp & Dohme LLC

Completed

An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)

Condylomata Acuminata
Jun Zhang
Xiamen Innovax Biotech Co., Ltd; Xiamen Center for Disease Control and Prevention

Completed

Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®）

Hepatitis E

China
National Institute of Allergy and Infectious Diseases...

Terminated

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
Jun Zhang
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Completed

A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls

Cervical Cancer | Cervical Intraepithelial Neoplasia | Vaginal Intraepithelial Neoplasia | Vulvar Intraepithelial Neoplasia | Persistent Infection

China
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Completed

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

Kidney Cancer

United States
Novartis Vaccines

Completed

Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10

Meningococcal Disease | Meningococcal Meningitis

Chile
Rockefeller University

Completed

Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers

Hepatitis B

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children

Virus Diseases

Mali, Senegal
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian... and other conditions

United States
Serum Institute of India Pvt. Ltd.
University of Stellenbosch; South African Tuberculosis Vaccine Initiative; Vakzine... and other collaborators

Completed

Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa

Tuberculosis

South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2

Dengue

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
Wiseman Research Initiatives LLC

Terminated

Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers

Breast Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
International AIDS Vaccine Initiative
National Institute of Allergy and Infectious Diseases (NIAID); Children's Hospital...

Unknown

A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.

HIV Infections

United Kingdom
Imperial College London
Medical Research Council

Completed

Safety and Immunogenicity of HIV DNA-C CN54ENV and Recombinant HIV CN54gp140 Vaccines in Healthy Volunteers

HIV

United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults

Virus Diseases

Mali, Senegal, Cameroon, Nigeria
Gamaleya Research Institute of Epidemiology and...

Completed

Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine "GamTBvac" Against the Tuberculosis. (GamTBvac)

Tuberculosis

Russian Federation
Oswaldo Cruz Foundation
IDRI; Biomedical Research Center EPLS; Orygen Biotecnologia SA

Completed

Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions

Schistosomiasis

Senegal
University of Oxford

Completed

Observational Study of Immune Response to Hepatitis B Childhood Booster

Healthy

United Kingdom
Xiamen Innovax Biotech Co., Ltd

Completed

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)

Hepatitis B | Hepatitis E

China
Jiangsu Province Centers for Disease Control and...
Third Military Medical University; Chengdu Olymvax Biopharmaceuticals Inc.

Completed

A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

Staphylococcus Aureus Infection

China
Protein Sciences Corporation
Kaiser Permanente

Completed

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

Human Influenza

United States
Novartis Vaccines
GlaxoSmithKline

Completed

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Serogroup B Meningococcal Meningitis

Austria, Czechia, Finland, Germany, Italy
UMN Pharma Inc.

Completed

A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers

Healthy

Japan
UMN Pharma Inc.

Completed

A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers

Healthy | Immunogenicity of ASP7374

Japan
U.S. Army Medical Research and Development Command

Withdrawn

Intranasal Recombinant Flagellin Subunit Campylobacter Vaccine (rFla-MBP) Dose-Ranging Study

Diarrhea

United States
National Cancer Institute (NCI)

Terminated

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Sanofi Pasteur, a Sanofi Company

Completed

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Virus Diseases | Bacterial Infections | Neisseria Meningitidis

Finland
Novartis Vaccines
GlaxoSmithKline

Completed

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Meningococcal Disease | Meningococcal Meningitis

Belgium, Czechia, Germany, Italy, Spain, United Kingdom
Johns Hopkins University
Merck Sharp & Dohme LLC

Completed

Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease

Chronic Kidney Disease

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors

Liver Neoplasms

United States
National Cancer Institute (NCI)

Completed

A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy

Prostatic Neoplasms

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

Influenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | H5N1 Virus | Orthomyxovirdae

United States
Sherief Abd-Elsalam

Unknown

Study of the Long Term Efficacy of Recombinant Hepatitis B Vaccine in Nile Delta of Egypt

Hepatitis B Vaccines

Egypt
Novartis Vaccines
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

Hepatitis B | Hepatitis A | Meningococcal Disease | Meningococcal Meningitis

Germany
Novartis Vaccines
GlaxoSmithKline

Completed

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

Prevention of the Meningococcal Disease

Germany

3

Subscribe